article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. It accounts for the majority of big data in healthcare and comprises information, such as medical images, surveys, chats, and written narratives.

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. Advances in quantum computing are also showing early promise for increasingly complex data analyses.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection. What, then, is the solution?

article thumbnail

Ventus and Novo Nordisk enter NLRP3 inhibitor development deal

Pharmaceutical Technology

According to the deal, Ventus is entitled to receive a $70m upfront payment in cash from Novo Nordisk and financing for the research and development (R&D). NLRP3 belongs to a family of proteins called inflammasome receptors. The company will also retain the global rights to its brain-penetrant NLRP3 inhibitor programme.

article thumbnail

Genmab’s Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics

XTalks

As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.

article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

The drug target for Penicillin is a protein that helps bacteria to synthesise its cell wall. One of the first and most basic requirements for a protein to be characterised as a drug target is to show that inhibiting its function prevents the disease. Big data handling and machine learning made progress by leaps.